🔴 Citius Pharmaceuticals is trading 6.03% down in after-hours trading after announcing fiscal third-quarter 2026 results with a net loss per share of $0.34, which was narrower than analyst estimates.

Citius Pharmaceuticals is trading 6.03% down at $0.71 in after-hours trading after releasing fiscal third-quarter 2026 results on August 14, 2026. The company reported a net loss per share of $0.34, which was narrower than analyst estimates of a $0.36 loss per share. LYMPHIR generated $1.5 million in quarterly revenue, and reported revenue for the first nine months reached $7.1 million. Regular-session close was $0.76; the company-specific earnings reaction is the most likely explanation for the after-hours movement.